Michigan Institute of Urology | Strategic Alliance Partners

The TAVT-45 formulation of abiraterone acetate was created for patients with dysphagia, who would have difficulty swallowing a tablet.

In an interview during the 2022 LUGPA Annual Meeting, Jason M. Hafron, MD, shared advice on optimizing advanced prostate cancer clinics, recapped the biggest advances in urologic cancer treatment in 2022, and discussed how Jelmyto treatment for UTUC has evolved over time.

"We're seeing that it's beneficial to the patient—it’s easier, they don't require a general anesthetic, and we don't have to bring him to the hospital," says Dr. Hafron.

The TAVT-45 formulation of abiraterone consists of granules for oral suspension and was created for patients with dysphagia who would have difficulty swallowing a tablet.

“We know that erectile dysfunction is really an important issue that can be a harbinger for other underlying cardiovascular or neurological health issues,” says Michael Lutz, MD.

“I think it's really important to understand the role of prevention and early detection,” says Michael Lutz, MD.

“While we have these young men in our offices, we need to try and engage them for all of the necessary screening opportunities that will improve the quality of their lives moving forward,” says Michael Lutz, MD, in this podcast episode.

“As urologists, we see men of all ages, and one of the things that we need to do is…take advantage of being their advocates for health care,” says Michael Lutz, MD.

"The biggest improvement in my patients has been the urgency frequency and urgency incontinence, and even some of the patients with irritable bowel," says David W. Law, DO.

“I think the main thing is placement of the neural probe on the first go around,” says David W. Law, DO.

“I think this really gave us an advantage to offer better care,” says Shiva J. Maralani, MD.

In this interview, Kenneth M. Kernen, MD, describes his practice’s Jelmyto program and offers advice for urologists interested in implementing it in their practice.

In this video, Ryan J. Nelson, DO, and Steven Ogilvy, PA-C, demonstrate the retroperitoneal single-port robotic surgical technique for a kidney tumor.

MIU seizes innovation opportunities presented by dynamic national urology platform caring for nearly one-half million patients.

In this interview, Jason M. Hafron, MD, discusses the “buzz” surrounding the meeting and touches on clinical topics including germline and somatic testing, PARP inhibitors, and mitomycin-containing reverse thermal gel (Jelmyto).

“[Out] of everything going on, this is probably 1 of the most exciting areas in prostate cancer,” says Jason M. Hafron, MD.

“I think as our understanding of mutations [and] our understanding the PARP inhibitors [grows], if the data pans out, we'll be using these earlier and earlier in patients, which I think we'll [will allow us to] see probably more benefit,” says Jason M. Hafron, MD.

“The future in bladder cancer [and] prostate cancer is really exploding. The therapeutics are coming faster than we ever thought,” says Jason M. Hafron, MD.

“What's great about [Jelmyto] is you can avoid a pretty morbid operation in a typically unhealthy older population, and treat them with localized therapy,” says Jason M. Hafron, MD.

“It's very important that the urologists get involved with germline and somatic testing,” says Jason M. Hafron, MD.

Determining grade of disease is important, as nephron-sparing approaches may be feasible.